Anthracyclines are among the most active cytotoxic drugs against breast cancer and are currently considered to be the standard agents for the adjuvant treatment of patients with node positive breast cancer. Nevertheless, the benefits attained by the use of the more active anthracycline schedules must be balanced against increased short- and long-term toxicity, and treatment options must be individualized for each patient. The authors review the available data regarding anthracycline efficacy and toxicity in the early breast cancer setting, the controversial issues still pending, and the potential directions for future research.
American Journal of Cancer – Springer Journals
Published: Aug 9, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.